Alison Birtle
A5079820994- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Epigenetics and DNA Methylation
- Renal cell carcinoma treatment
- Multiple and Secondary Primary Cancers
- Testicular diseases and treatments
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Urological Disorders and Treatments
- Cancer Genomics and Diagnostics
- Ethics in Clinical Research
- Advanced Radiotherapy Techniques
- Esophageal Cancer Research and Treatment
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Patient-Provider Communication in Healthcare
- Hormonal and reproductive studies
- Bone health and treatments
- DNA Repair Mechanisms
- Brain Metastases and Treatment
Lancashire Teaching Hospitals NHS Foundation Trust
2016-2025
University of Manchester
2014-2025
University of Central Lancashire
2021-2025
Royal Preston Hospital
2015-2024
University Hospitals of Morecambe Bay NHS Foundation Trust
2018-2024
Institute of Cancer Research
2009-2024
Beatson West of Scotland Cancer Centre
2012-2024
University of Glasgow
2020-2024
Rosemere Cancer Foundation
2016-2022
Cancer Research UK Manchester Institute
2019-2022
BackgroundLong-term hormone therapy has been the standard of care for advanced prostate cancer since 1940s. STAMPEDE is a randomised controlled trial using multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent who are starting first-line long-term therapy. We report primary survival results three research comparisons testing addition zoledronic acid, docetaxel, their combination to versus alone.MethodsStandard was at least 2 years;...
Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design.
BackgroundProstate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present pre-planned analysis of the efficacy and side-effects randomised trial comparing conventional radiotherapy after 5 years follow-up.MethodsCHHiP is randomised, phase 3, non-inferiority recruited men with localised prostate (pT1b–T3aN0M0). Patients were randomly assigned (1:1:1) (74 Gy delivered in 37 fractions over 7·4 weeks) or one two...
BackgroundBased on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic cancer, and benefit be greatest patients a low burden. We aimed compare standard of care for without radiotherapy.MethodsWe did randomised controlled phase 3 trial at 117 hospitals Switzerland UK. Eligible had newly diagnosed cancer. randomly allocated open-label 1:1 ratio (control group) or (radiotherapy group). Randomisation was stratified by...
BackgroundUrothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis than urothelial bladder. No international consensus exists on benefit adjuvant chemotherapy for patients UTUCs after nephroureterectomy curative intent. The POUT (Peri-Operative versus sUrveillance in Tract cancer) trial aimed to assess efficacy systemic platinum-based UTUCs.MethodsWe did a phase 3, open-label, randomised controlled at 71 hospitals UK. We recruited UTUC staged...
BackgroundSTAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on outcomes stratified by burden M1 patients.MethodsWe randomly allocated in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox...
Adding abiraterone acetate with prednisolone (AAP) or docetaxel (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced metastatic prostate cancer: evaluation of drug efficacy: a multi-arm multi-stage platform randomised controlled protocol recruiting patients high-risk locally PCa starting long-term androgen deprivation (ADT). The provides the only direct, comparative data SOC + AAP versus DocP.
BackgroundAbiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed evaluate long-term and test whether combining abiraterone survival.MethodsWe analysed two open-label, randomised, controlled, phase 3 trials STAMPEDE platform protocol, no overlapping controls, conducted 117 sites in UK Switzerland. Eligible (no age restriction) had...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. POUT was a phase III, randomized, open-label trial, including 261 patients with muscle-invasive lymph...
The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role RT in node-positive (N+) M0 disease. STAMPEDE Trial includes such individuals, allowing an exploratory multivariate analysis impact radical RT.
Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality life (QoL) substudy to assess PROs up 24 months after conventionally fractionated or hypofractionated in the Conventional Hypofractionated High Dose Intensity Modulated Radiotherapy Prostate Cancer (CHHiP) trial.
Objectives To test the feasibility of a randomised trial in muscle‐invasive bladder cancer ( MIBC ) and compare outcomes patients who receive neoadjuvant chemotherapy followed by radical cystectomy RC or selective preservation SBP ), where definitive treatment [ radiotherapy RT )] is determined response to chemotherapy. Patients Methods SPARE multicentre controlled comparing with staged T2–3 N0 M0, fit for both strategies receiving three cycles were between before cystoscopy after cycle ≤T1...
Recruitment to randomised controlled trials (RCTs) with very different treatment arms is often difficult. The ProtecT (Prostate testing for cancer and Treatment) study successfully used qualitative research methods improve recruitment these were replicated in five other RCTs facing difficulties. A similar investigation was undertaken the SPARE (Selective bladder Preservation Against Radical Excision) feasibility explore reasons low attempt rates by implementing changes suggested findings. In...
5001 Background: STAMPEDE is a randomised controlled trial using novel multi-arm multi-stage design. It recruits men (pts) with high-risk locally advanced or metastatic prostate cancer (PCa) starting long-term hormone therapy (HT) for the first time. The initially assessed adding 1 2 of 3 treatment approaches to standard care (SOC). We report primary survival results research comparisons that recruited through all their intermediate analyses: docetaxel (D), zoledronic acid (ZA) & combination...
Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE--an international, open-label, randomised controlled trial--uses a novel multiarm, multistage design to assess whether the early additional use of one two drugs (docetaxel, zoledronic acid, celecoxib, acid and docetaxel, celecoxib) improves survival in men starting first-line, long-term therapy. Here, we report preplanned, second intermediate analysis comparing plus...
Background Randomised controlled trials (RCTs) are essential for evidence-based medicine and increasingly rely on front-line clinicians to recruit eligible patients. Clinicians' difficulties with negotiating equipoise is assumed undermine recruitment, although these issues have not yet been empirically investigated in the context of observable events. We aimed investigate how conveyed during RCT recruitment appointments across six RCTs, a view (i) identifying practices that supported or...
Background STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed cancer low metastatic burden, but not those high-burden disease. In this final analysis, we report long-term findings on primary outcome measure of OS and secondary measures symptomatic local events, RT toxicity quality life (QoL). Methods Patients were randomised at care sites in United Kingdom Switzerland between January 2013 September 2016,...
Abstract Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial men starting long‐term hormone therapy for prostate cancer. This analysis metastatic patients was planned 3 years after the first results. Standard‐of‐care (SOC) androgen deprivation therapy. The comparison randomised 1:1 to SOC‐alone with or without daily abiraterone 1000 mg + 5 (SOC AAP), continued until disease progression. primary outcome...